Candel Therapeutics Taps EVERSANA for U.S. Launch Preparation Ahead of Q4 2026 BLA Submission
Candel Therapeutics has signed a commercialization agreement with EVERSANA to support the potential U.S. launch of aglatimagene besadenovec for intermediate- to high-risk localized prostate cancer, following a planned BLA submission in Q4 2026. EVERSANA will deliver integrated services including data analytics, medical affairs, market access and field operations.
1. Commercialization Agreement Details
Candel Therapeutics entered into a product commercialization agreement with EVERSANA to support the potential U.S. launch of aglatimagene besadenovec for intermediate- to high-risk localized prostate cancer. Under the agreement, EVERSANA will provide a broad suite of integrated commercialization services, including data and analytics, medical affairs, market access and field operations.
2. BLA Submission and Pre-commercial Workstreams
Candel plans to submit a Biologics License Application in Q4 2026 for aglatimagene besadenovec and has been collaborating with IDEA Pharma on path-to-market strategies since December 2025. Key pre-commercial workstreams, such as strategic positioning and market assessment, are already underway to ensure readiness for regulatory approval.
3. Partner-led Commercial Model and Impact
Candel’s partner-led model leverages specialized service providers instead of a fixed infrastructure, preserving financial flexibility and capital efficiency. This approach allows the company to maintain scientific focus while accessing world-class commercial capabilities on demand, positioning aglatimagene for an efficient and scalable market entry upon approval.